Filing Details
- Accession Number:
- 0001104659-21-100843
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-08-05 17:18:56
- Reporting Period:
- 2021-08-03
- Accepted Time:
- 2021-08-05 17:18:56
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1722964 | Y-Mabs Therapeutics Inc. | YMAB | Pharmaceutical Preparations (2834) | 474619612 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1753224 | Thomas Gad | C/O Y-Mabs Therapeutics, Inc. 230 Park Avenue, Suite 3350 New York NY 10169 | See Remarks | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2021-08-03 | 4,000 | $33.73 | 1,583,927 | No | 4 | S | Indirect | By GAD Enterprises LLC |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | By GAD Enterprises LLC |
Footnotes
- Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2021.
- This transaction was executed in multiple trades at prices ranging from $33.20 to $34.43. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provideupon request to the SEC staff, the issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
- Reporting Person is sole member of GAD Enterprises, LLC and the sole member and manager of GAD Management, LLC, the manager of GAD Enterprises, LLC, and as such Reporting Person has sole voting and dispositive power with respect to such shares.